PATHOPHYSIOLOGY OF CUTANEOUS VASCULAR LESIONS
PATHOPHYSIOLOGY OF CUTANEOUS VASCULAR LESIONS
批准号:
6532911
负责人:
JACK L ARBISER
金额:
$10.84万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-09-15 至 2004-08-31
关键词:
SCID mouse angiogenesis angiogenesis factor angiogenesis inhibitors athymic mouse biological signal transduction densitometry enzyme activity gene expression gene induction /repression genetic regulation genetic transcription growth factor receptors hemangioma immunoprecipitation messenger RNA metalloendopeptidases mitogen activated protein kinase nuclear runoff assay pathologic process phosphatidylinositol 3 kinase scleroderma skin disorder vascular endothelium western blottings
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This Career Development Award Proposal focuses on the pathogenesis of
cutaneous vascular lesions. Hemangiomas are the most common cutaneous
vascular lesions of childhood, and are present in 10 percent of infants
at 1 year of age. These hemangiomas may grow to large size, resulting
in compression of vital structures, high output cardiac failure, and
coagulopathy. The coagulopathy phenomenon is known as the Kasabach-
Merritt syndrome. Treatment of large hemangiomas requires lengthy
treatment with steroids or alpha interferon, and surgery. A significant
number of these hemangiomas do not respond to treatment, resulting in
death.
Little is known of the pathophysiology of these lesions, but preliminary
evidence points to an imbalance of angiogenesis stimulators and
inhibitors. We have developed a murine model of proliferative vascular
lesions through the sequential introduction of SV40 large T antigen and
H-ras into endothelial cells. This model recapitulates clinical and
histologic features of both nonproliferative and proliferative
hemangiomas. I wish to study the signal transduction pathways involved
in upregulation of angiogenesis stimulators and downregulation of
angiogenesis inhibitors. In addition, I have found that transformed
endothelial cells express both VEGF and its receptor, flk-1, suggesting
a possible autocrine loop. Finally, the novel angiogenesis inhibitor
endostatin has been isolated from a spontaneous hemangioendothelioma
cell line. Its mechanism of action is unknown. I hope to learn the
signal transduction pathways through which endostatin mediates
angiogenesis inhibition. Interruption of angiogenic autocrine loops and
targeting of signal transduction pathways activated in proliferative
vascular lesions may provide novel therapies for hemangiomas.
The Folkman laboratory has extensive experience in the isolation and
characterization of angiogenesis stimulators and inhibitors. In order
to become an independent investigator in angiogenesis, proficiency in
these techniques is necessary. The opportunity to carry out the studies
outlined in this proposal and receive formal training in cell biology,
protein purification and characterization, and surgical procedures will
afford the applicant the training which is required toward the
establishment of his career as an independent physician-scientist.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Regulation of angiogenesis and tumorigenesis by signal transduction cascades: lessons from benign and malignant endothelial tumors.
通过信号转导级联调节血管生成和肿瘤发生:良性和恶性内皮肿瘤的教训。
DOI:
10.1046/j.1087-0024.2000.00007.x
发表时间:
2000
期刊:
The journal of investigative dermatology. Symposium proceedings
影响因子:
--
作者:
[Klafter,R, Arbiser,JL]
通讯作者:
Arbiser,JL
Ceramide Analog Control of Cutaneous Inflammation
-
批准号:10368633
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:JACK L ARBISER
-
依托单位:
Palladium based nanoparticles for the treatment of advanced melanoma
-
批准号:9206894
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:JACK L ARBISER
-
依托单位:
Skin Manifestations of Tuberous Sclerosis
-
批准号:7674820
-
项目类别:
-
资助金额:$21.89万
-
财政年份:2005
-
负责人:JACK L ARBISER
-
依托单位:
Skin Manifestations of Tuberous Sclerosis
-
批准号:7483282
-
项目类别:
-
资助金额:$21.89万
-
财政年份:2005
-
负责人:JACK L ARBISER
-
依托单位:
Skin Manifestations of Tuberous Sclerosis
-
批准号:7035486
-
项目类别:
-
资助金额:$23.56万
-
财政年份:2005
-
负责人:JACK L ARBISER
-
依托单位:
Skin Manifestations of Tuberous Sclerosis
-
批准号:7278673
-
项目类别:
-
资助金额:$22.34万
-
财政年份:2005
-
负责人:JACK L ARBISER
-
依托单位:
Skin Manifestations of Tuberous Sclerosis
-
批准号:7126507
-
项目类别:
-
资助金额:$23.01万
-
财政年份:2005
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:6649140
-
项目类别:
-
资助金额:$25.27万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:8856496
-
项目类别:
-
资助金额:$34.32万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:8103817
-
项目类别:
-
资助金额:$25.93万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:7526359
-
项目类别:
-
资助金额:$27.28万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:7902102
-
项目类别:
-
资助金额:$27.01万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:8289627
-
项目类别:
-
资助金额:$25.93万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:6783467
-
项目类别:
-
资助金额:$25.27万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:7677372
-
项目类别:
-
资助金额:$27.28万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:6912811
-
项目类别:
-
资助金额:$25.27万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:6364997
-
项目类别:
-
资助金额:$25.27万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:6512122
-
项目类别:
-
资助金额:$25.27万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
Cutaneous Hemangiomas and Signal Transduction
-
批准号:9070292
-
项目类别:
-
资助金额:$34.32万
-
财政年份:2001
-
负责人:JACK L ARBISER
-
依托单位:
ROLE OF CORTICOTROPIN RELEASING HORMONE IN ANGIOGENESIS
-
批准号:6100605
-
项目类别:
-
资助金额:$6.87万
-
财政年份:1999
-
负责人:JACK L ARBISER
-
依托单位:
国内基金
海外基金
ROBO4对视网膜血管生成(angiogenesis)的调控及其分子机制
-
批准号:81200692
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2012
-
负责人:陈凌
-
依托单位: